Login / Signup

Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET.

Sinan WangJun LiJun HuaYang SuDenis R Beckford-VeraWalter ZhaoMayuri JayaramanTony L HuynhNing ZhaoYangjie HuangFujun QinSui ShenDaniel GioeliRobert DreicerRenuka SriramEmily A EgusaJonathan ChouFelix Y FengRahul AggarwalKenneth W BaylesYoungho SeoBin LiuRobert R FlavellJiang He
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
[89Zr]DFO-YS5 is an excellent PET imaging agent across a panel of prostate cancer models, including in both adenocarcinoma and neuroendocrine prostate cancer, both cell line- and patient-derived xenografts, and both PSMA-positive and -negative tumors. It demonstrates potential for clinical translation as an imaging agent, theranostic platform, and companion biomarker in prostate cancer.
Keyphrases
  • prostate cancer
  • pet imaging
  • radical prostatectomy
  • squamous cell carcinoma
  • high resolution
  • photodynamic therapy
  • computed tomography
  • pet ct
  • drug delivery
  • fluorescence imaging